Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study

被引:1
|
作者
Praiss, Aaron M. [1 ]
Hirani, Rahim [1 ]
Zhou, Qin [1 ]
Iasonos, Alexia [1 ]
Sonoda, Yukio [1 ,2 ]
Abu-Rustum, Nadeem R. [1 ,2 ]
Leitao Jr, Mario M. [1 ]
Roche, Kara Long [1 ,2 ]
Broach, Vance [1 ,2 ]
Gardner, Ginger J. [1 ,2 ]
Chi, Dennis S. [1 ,2 ]
Zivanovic, Oliver [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY USA
[2] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Intestinal resection; Postoperative morbidity; Anastomotic leak; Ovarian cancer; Primary cytoreductive surgery; Interval cytoreductive surgery; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; RECTOSIGMOID RESECTION; BOWEL RESECTIONS; FALLOPIAN-TUBE; RISK; ALGORITHM; SURVIVAL; DELAY;
D O I
10.1016/j.ygyno.2023.10.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestinal resection. Methods. A retrospective chart review was performed for patients with ovarian cancer who underwent PCS or ICS with at least one intestinal resection at our institution from 1/1/2015 to 12/31/2020. Progression-free survival (PFS) and overall survival (OS) were analyzed for the PCS and ICS cohorts separately. Short-term complications within 30 days of surgery (surgical secondary events [SSEs]) were graded by a validated institutional SSE system. Results. Among 437 patients who underwent intestinal resections during PCS (n = 289) or ICS (n = 148), 183 (42%) had one, 180 (41%) had two, and 74 (17%) had three intestinal resections. Six (1.4%) of 437 patients experienced an anastomotic leak postoperatively. There were no perioperative deaths. There was no difference in PFS and OS for patients who underwent PCS with any SSE vs. no SSE within 30 days of surgery (HR, 1.05; 95% CI: 0.76-1.47; p = 0.75 and HR, 0.79; 95% CI: 0.49-1.26; p = 0.32, respectively). There was no difference in PFS and OS for patients who underwent ICS with any SSE vs. no SSE within 30 days of surgery (HR, 1.43; 95% CI: 0.99-2.07; p = 0.055 and HR. 1.18; 95% CI: 0.72-1.93; p = 0.52, respectively. Conclusion. Short-term postoperative morbidity for patients who underwent intestinal surgery during primary surgical management for advanced ovarian cancer did not impact oncologic outcomes. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:169 / 179
页数:11
相关论文
共 50 条
  • [41] PROGNOSTIC IMPACT OF THE TIME INTERVAL BETWEEN PRIMARY SURGERY AND CHEMOTHERAPY IN THE TREATMENT OF EPITHELIAL OVARIAN CANCER
    Fournier, M.
    Huchon, C.
    Bats, A. S.
    Lecuru, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1565 - 1565
  • [42] PROGNOSTIC IMPACT OF THE TIME INTERVAL BETWEEN PRIMARY SURGERY AND CHEMOTHERAPY IN THE TREATMENT OF EPITHELIAL OVARIAN CANCER
    Fournier, M.
    Huchon, C.
    Bats, A. S.
    Bensaid, C.
    Ngo, C.
    Lecuru, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1344 - 1344
  • [43] PROGNOSTIC IMPACT OF THE TIME INTERVAL BETWEEN PRIMARY SURGERY AND CHEMOTHERAPY IN THE TREATMENT OF EPITHELIAL OVARIAN CANCER
    Fournier, M.
    Huchon, C.
    Bats, A. S.
    Ngo, C.
    Bensaid, C.
    Douay-Hauser, N.
    Seror, J.
    Poupon, C.
    Dessapt, A. L.
    Lecuru, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 306 - 306
  • [44] A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO
    Sinukumar, Snita
    Rajan, Firoz
    Mehta, Sanket
    Damodaran, Dileep
    Zaveri, Shabber
    Kammar, Praveen
    Bhatt, Aditi
    EJSO, 2021, 47 (01): : 75 - 81
  • [45] MORBIDITY OF RECTOSIGMOID RESECTION IN PATIENTS UNDERGOING CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN CANCER. RISK FACTORS FOR COMPLICATION.
    Fournier, M.
    Huchon, C.
    Bats, A. S.
    Bensaid, C.
    Ngo, C.
    Lecuru, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 427 - 427
  • [46] Comparison of longitudinal patient reported outcomes on an enhanced recovery pathway in patients with ovarian cancer undergoing primary vs interval cytoreductive surgery
    Meyer, L. A.
    Nick, A. M.
    Shi, Q.
    Iniesta, M. D.
    Lasala, J. D.
    Harris, M.
    Sun, C. C. L.
    Lu, K. H.
    Ramirez, P. T.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 207 - 208
  • [47] PROGNOSTIC IMPACT OF THE TIME INTERVAL FROM SURGERY TO CHEMOTHERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
    Shim, S. H.
    Kim, D. Y.
    Lee, S. W.
    Park, J. Y.
    Dae-Sik, S.
    Kim, J. H.
    Kim, Y. M.
    Kim, Y. T.
    Nam, J. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1665 - 1665
  • [48] PROGNOSTIC IMPACT OF THE TIME INTERVAL FROM SURGERY TO CHEMOTHERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
    Shim, S. H.
    Kim, D. Y.
    Lee, S. W.
    Park, J. Y.
    Dae-Sik, S.
    Kim, J. H.
    Kim, Y. M.
    Kim, Y. T.
    Nam, J. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 532 - 532
  • [49] Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer
    Colombo, P. E.
    Labaki, M.
    Fabbro, M.
    Bertrand, M.
    Mourregot, A.
    Gutowski, M.
    Saint-Aubert, B.
    Quenet, F.
    Rouanet, P.
    Mollevi, C.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 223 - 230
  • [50] Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
    Bhatt, Aditi
    Sinukumar, Snita
    Kepenekian, Vahan
    Kammar, Praveen
    Mehta, Sanket
    Shaikh, Sakina
    Gertych, Witold
    Bakrin, Naoual
    Glehen, Olivier
    FRONTIERS IN ONCOLOGY, 2022, 12